Par Drugs And Chemicals Limited · NSE:PAR
Par Drugs And Chemicals — Q3 2023 Earnings Presentation
16 slides from Par Drugs And Chemicals's earnings presentation, Feb 20, 2023
Slide 1: Cover letter to NSE: Investors Presentation
PAR/CS/NSE/2022-23/58 To, Date: 20/02/2023 The Manager Listing department, National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra (E), Mumbai- 400 051 Maharashtra Symbol - PAR, ISIN: INE04LG01015 Subject: Investors Presentation Ref.: Regulation 30 read wi
Slide 2: Q3/9M-FY23 Earnings Presentation
Q3/9M-FY23 Earnings Presentation
Slide 3: Company Overview
Company Overview
Slide 4: Company Overview
3 Company Overview Operational Revenues (INR Mn) • Promoted by Mr. Falgun Savani and Mr. Jignesh Savani, Par Drugs and Chemicals Limited (PDCL) was founded in 1982 and is engaged in the development 209 and manufacturing of APIs. 298 194 218 • The Company today manufactures 25 different products and
Slide 5: Key Strengths
4 Key Strengths Diversified Portfolio: The company manufactures the entire range of products in the Antacid segment. The product portfolio presently comprises 15 APIs and 10 Fine Chemicals which are marketed domestically and exported. Global Presence: The Company is operating both in domestic and ex
Slide 6: Financial & Operational Highlights
FINANCIAL & OPERATIONAL HIGHLIGHTS
Slide 7: Q3/9M-FY23 Financial & Operational Highlights
6 Q3/9M-FY23 Financial & Operational Highlights Q3-FY23 Financial Highlights Operational Highlights • The company witnessed healthy growth on a YoY basis, driven by sales growth in the domestic market by 39% and in the export Revenue EBITDA EBITDA Margin market by 19% against the same period in the
Slide 8: Q3/9M-FY23 Financial Overview
Q3/9M-FY23 Financial Overview
Slide 9: Quarterly Income Statement (IND-AS)
8 Quarterly Income Statement (IND-AS) Income Statement (INR Mn) Q3-FY23 Q3-FY22 Y-o-Y Q2-FY23 Q-o-Q Income from Operations 229 169 35.5% 248 (7.7)% Total Expenses 197 134 47.0% 189 4.2% EBITDA 32 35 (8.6)% 59 (45.8)% EBITDA Margins (%) 13.97% 20.71% (674) Bps 23.79% (982) Bps Finance Cost 0 1 NA 0 N
Slide 10: YTD Income Statement (IND-AS)
9 YTD Income Statement (IND-AS) Income Statement (INR Mn) 9M-FY23 9M-FY22 Y-o-Y Income from Operations 713 530 34.5% Total Expenses 585 412 42.0% EBITDA 128 118 8.5% EBITDA Margins(%) 17.95% 22.26% (431) Bps Finance Cost 1 4 (75.0)% Depreciation 24 24 NA Other Income 2 1 NA Profit Before Tax 105 91
Slide 11: Historical Income Statement
10 Historical Income Statement Income Statement (INR Mn) FY20 FY21 FY22 9M-FY23 Income from Operations 558 608 751 713 Total Expenses 464 447 588 585 EBITDA 94 161 163 128 EBITDA Margins (%) 16.85% 26.48% 21.70% 17.95% Finance Cost 8 7 5 1 Depreciation 27 28 33 24 Other Income 1 2 2 2 Profit before
Slide 12: Balance Sheet
11 Balance Sheet EQUITIES & LIABILITIES (INR Mn) FY21 FY22 H1-FY23 ASSETS (INR Mn) FY21 FY22 H1-FY23 Shareholder Funds 522 599 659 Non Current Assets 352 351 363 (A) Equity Share Capital 61 123 123 (A) Fixed Assets - - - (B) Reserves & Surplus 461 476 536 (i) Tangible Assets 299 341 331 (ii) Capital
Slide 13: Financial Highlights
12 Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 751 713 26.48% 19.08% 608 21.70% 558 16.85% 17.95% 12.25% 11.08% 8.60% 116 92 79 94 161 163 128 48 FY20 FY21 FY22 9M-FY23 FY20 FY21 FY22 9M-FY23 FY20 FY21 FY22 9M-FY23 RoCE & RoE
Slide 14: Capital Market Highlights
13 Capital Market Highlights Stock Market Performance (as on 31st December, 2022) 20% 0% -20% -40% 03-Jan 03-Feb 03-Mar 03-Apr 03-May 03-Jun 03-Jul 03-Aug 03-Sep 03-Oct 03-Nov 03-Dec Par Drugs Nifty 50 52 Price Data (31st December, 2022) INR Shareholding Pattern as on 31st December, 2022 Face Value
Slide 15: Disclaimer
14 Disclaimer Par Drugs and Chemicals Limited: The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection w
Slide 16: Thank You
Thank You
Par Drugs and Chemicals — Q3 2023 Earnings Presentation on 6ix